What is the 13F Pro Quality Score for KPTI?

13F Pro ranks Karyopharm Therapeutics Inc. (KPTI) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View KPTI's current score at https://13fpro.ai/research/KPTI (free sign-up required for the full ranking).

Where does 13F Pro source KPTI data?

All Karyopharm Therapeutics Inc. fundamentals and ownership data come directly from SEC EDGAR. Karyopharm Therapeutics Inc. files with the SEC under CIK 1503802. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is KPTI in?

Karyopharm Therapeutics Inc. (KPTI) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is KPTI research updated on 13F Pro?

KPTI's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Karyopharm Therapeutics Inc.(KPTI)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1503802 KPTI stock profile & AI dashboard →

13F Pro Quality Score

20.4/100

Rank #2,675 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

34.6/100

Profitability

8.0/100

Balance Sheet

0.5/100

Earnings Quality

30.0/100

Free Cash Flow

8.6/100

Institutional Flow

99.7/100

Revenue Scale

20.9/100

Dilution Risk

17.3/100

KPTI Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Karyopharm Therapeutics Inc. (KPTI), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores KPTI at 20.4/100 on a 32-signal composite quality model, placing it at rank #2,675 of 2,879 stocks — the bottom half of the AI-ranked universe. KPTI scores in the top quartile across institutional flow (99.7). Areas of concern include balance sheet strength (0.5) and profitability (8.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 17.3/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Karyopharm Therapeutics Inc. reports quarterly revenue of $35.1M, net income of $-22.4M, an operating margin of -76.3%. Top institutional holders of KPTI by reported 13-F value include Commodore Capital, RA CAPITAL MANAGEMENT, L.P., ADAGE CAPITAL PARTNERS GP, L.L.C., based on the most recent SEC filings. KPTI trades on the Nasdaq exchange and files with the SEC under CIK 1503802. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate KPTI daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Karyopharm Therapeutics Inc. directly from SEC EDGAR. Karyopharm Therapeutics Inc.'s 13F Pro composite quality score has ranged between 11 and 31 since 2021, currently 20.4 — a declining long-term trajectory across 30 quarterly and live scoring snapshots.

✦

Fun facts about Karyopharm Therapeutics Inc.

Quirks, history, and lore behind KPTI — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. biopharmaceutical company · small-cap · listed on Nasdaq · headquartered in Massachusetts.
2
The Numbers
Annual revenue in the low hundreds of millions of dollars, driven almost entirely by a single approved drug — a common situation for a focused oncology biotech.
3
The History
Founded in the early 2000s, the company spent years cracking a little-known but critical piece of cell biology before earning its first FDA approval for a blood cancer treatment.
4
The Secret
Its entire scientific identity is built around blocking a protein called XPO1 — a cellular gatekeeper that cancer cells hijack to survive. Shut the gate, kill the cancer.
5
The Lore
Its lead drug, selinexor, targets multiple myeloma and certain lymphomas — diseases that have long chewed through other therapies — giving patients a new mechanism of attack when others fail.
6
The Giveaway
The name is practically a spoiler: it's built from the word karyopherin — the family of proteins it studies — and its ticker even nods to the nuclear export pathway it was founded to exploit.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$35.1M

Net Income

Q1 2026

$-22.4M

Free Cash Flow

Q1 2026

$-22.7M

Operating Margin

Q1 2026

-76.3%

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+0.6% YoY

$146.1MFY 2025

FY22 $157.1MFY23 $146.0MFY24 $145.2MFY25 $146.1M

Net Income

-156.5% YoY

$-196.0MFY 2025

FY22 $-165.3MFY23 $-143.1MFY24 $-76.4MFY25 $-196.0M

Operating Income

+24.1% YoY

$-90.7MFY 2025

FY22 $-142.2MFY23 $-129.5MFY24 $-119.4MFY25 $-90.7M

EPS (Diluted)

-28.1% YoY

$-17.93FY 2025

FY22 $-2.02FY23 $-18.79FY24 $-14.00FY25 $-17.93

Total Assets

-34.1% YoY

$108.4MFY 2025

FY22 $358.2MFY23 $240.4MFY24 $164.4MFY25 $108.4M

Total Debt

—FY 2025

FY22 —FY23 —FY24 —FY25 —

Op. Cash Flow

+40.9% YoY

$-75.4MFY 2025

FY22 $-149.6MFY23 $-92.7MFY24 $-127.5MFY25 $-75.4M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$146.1M +0.6%	$145.2M -0.5%	$146.0M -7.0%	$157.1M -25.1%	$209.8M +94.1%	$108.1M
Net Income	$-196.0M -156.5%	$-76.4M +46.6%	$-143.1M +13.4%	$-165.3M -33.2%	$-124.1M +36.8%	$-196.3M
Operating Income	$-90.7M +24.1%	$-119.4M +7.8%	$-129.5M +8.9%	$-142.2M -44.7%	$-98.3M +42.8%	$-171.8M
EPS (Diluted)	$-17.93 -28.1%	$-14.00 +25.5%	$-18.79 -830.2%	$-2.02 -22.4%	$-1.65 +39.3%	$-2.72
Total Assets	$108.4M -34.1%	$164.4M -31.6%	$240.4M -32.9%	$358.2M +17.3%	$305.3M -2.5%	$313.1M
Total Debt	—	—	—	—	$169.3M	—
Operating Cash Flow	$-75.4M +40.9%	$-127.5M -37.5%	$-92.7M +38.0%	$-149.6M -39.6%	$-107.1M +33.2%	$-160.2M

AI Insight: KPTI Financial Trends

Revenue stalled near $35M while accumulated losses eroded equity to -$266M; operating cash burn remains substantial despite margin improvements.

• Operating income deficit narrowed from -$33M in Q1 2025 to -$27M in Q1 2026, showing operational leverage.

• Operating cash outflow improved from -$39M in Q1 2025 to -$23M in Q1 2026, reducing quarterly burn.

• Revenue declined from $43M in Q2 2024 to $35M in Q1 2026, a 19% contraction over nine quarters.

⚠ Negative equity deteriorated to -$266M in Q1 2026 from -$132M in Q2 2024; solvency risk intensifying.

⚠ Q4 2025 net loss spiked to -$102M; investigate one-time charge or valuation write-down impact.

AI Insight: KPTI Ratio Trends

Operating margin volatility masks underlying cash burn; no clear stabilization path visible through Q1 2026.

• Operating margin improved from -110.8% in Q1 2025 to -76.3% in Q1 2026, but remains deeply negative with high quarter-to-quarter swings.

• Net profit margin deteriorated from -78.2% in Q1 2025 to -63.9% in Q1 2026, indicating persistent losses despite operational improvements.

• Return on assets stayed severely negative at -68.2% in Q1 2026, comparable to -73.5% in Q1 2025.

⚠ Operating margin swung 77.8 percentage points from Q3 2025 (-34.6%) to Q1 2026 (-76.3%), suggesting erratic cost structure or one-time charges.

⚠ Company remains unprofitable across all reported metrics with no equity value (ROE/ROIC unavailable), indicating negative tangible value.

Get alerted when KPTI's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Karyopharm Therapeutics Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of KPTI

Commodore Capital LP
$10.9M1,950,000 sh
RA CAPITAL MANAGEMENT, L.P.
$10.7M1,917,354 sh
ADAGE CAPITAL PARTNERS GP, L.L.C.
$10.1M1,806,322 sh
Caption Management, LLC
$6.1M1,086,900 sh
GOLDMAN SACHS GROUP INC
$5.3M947,579 sh
Ikarian Capital, LLC
$5.1M920,000 sh
Ikarian Capital, LLC
$5.1M920,000 sh
Catalio Capital Management, LP
$5.0M897,709 sh
SUSQUEHANNA INTERNATIONAL GROUP, LLP
$4.8M865,000 sh
Squadron Capital Management LLC
$4.2M750,000 sh

Fund	Value	Shares
Commodore Capital LP	$10.9M	1,950,000
RA CAPITAL MANAGEMENT, L.P.	$10.7M	1,917,354
ADAGE CAPITAL PARTNERS GP, L.L.C.	$10.1M	1,806,322
Caption Management, LLC	$6.1M	1,086,900
GOLDMAN SACHS GROUP INC	$5.3M	947,579
Ikarian Capital, LLC	$5.1M	920,000
Ikarian Capital, LLC	$5.1M	920,000
Catalio Capital Management, LP	$5.0M	897,709
SUSQUEHANNA INTERNATIONAL GROUP, LLP	$4.8M	865,000
Squadron Capital Management LLC	$4.2M	750,000

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put KPTI on your watchlist

Track score changes the day Karyopharm Therapeutics Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is KPTI a good stock to buy?

13F Pro's AI-powered analysis of Karyopharm Therapeutics Inc. (KPTI) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for KPTI are available on the KPTI stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own KPTI?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling KPTI. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Karyopharm Therapeutics Inc.'s investment landscape.